Rui Zhang

Rui Zhang

Auto-generated profile, based on publicly available information

Rui Zhang

School of Nursing, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province 210000, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YYYao Yao
Yao Yao
LZLin Zhou
Lin Zhou
FCFeng-Qin Chen
Feng-Qin Chen
RZRui Zhang
Rui Zhang
XPXiang-Tian Pang
Xiang-Tian Pang
ZSZhi-ling Sun
Zhi-ling Sun
Background. Low back pain (LBP) is considered the leading cause of people living with years of disability worldwide. Notably, thunder-fire moxibustion (TFM) is a new type of moxibustion, which has been widely applied to treat pain syndromes for thousands of years. This study aims to provide evidence to evaluate the effect and safety of TFM in treating LBP. Methods. A systematic search of PubMed, Web of Science, the Cochrane Library, Embase, EBSCO, CNKI, Wanfang Data, CBM, and VIP (until April 2021) was used to identify studies reporting pain intensity, disability, Japanese Orthopedic Association (JOA) score, and quality of life in patients with LBP. Randomized controlled trials (RCTs), which compared TFM and other therapies in LBP, were included. Meanwhile, methodological quality was evaluated using the Cochrane criteria for risk of bias, and the level of evidence was rated utilizing the GRADE approach. Results. Twenty-one RCTs, including 2198 patients, satisfied the inclusion criteria. Compared with other therapies, the effect of TFM was statistically significant, pain intensity decreased (SMD = 0.94; 95% CI (0.74, 1.14); ), disability improved (SMD = 1.39; 95% CI (0.19, 2.59); ), and the JOA score increased (SMD = −1.34; 95% CI (−1.88, −0.80); ). It was also reported that the patient’s quality of life improved after treatment for a period of 4 weeks (SMD = −0.29; 95% CI (−0.42, −0.16); ) and after a follow-up of 1 month (SMD = −0.20; 95% CI (−0.34, −0.07); ). The evidence level of the results was determined to be very low to low. Conclusions. Based on the existing evidence, it can be concluded that TFM may have a better effect than other treatments on LBP. However, it is not yet possible to assess the safety level of TFM therapy. Due to the universal low quality of the eligible trials and low evidence level, rigorously designed large-scale RCTs must be conducted in order to further confirm the results in this review.